渤健公司高管近日透露，公司预计2026年多发性硬化症产品线的整体销售额（不含Vumerity）将出现中等两位数百分比的下滑，较2025年同期下降约15%。这一预测反映了市场竞争加剧及专利到期对核心产品带来的持续压力。不过，新一代口服药物Vumerity仍被排除在此次下滑预期之外，显示出公司对创新产品市场表现的信心。
渤健公司高管近日透露，公司预计2026年多发性硬化症产品线的整体销售额（不含Vumerity）将出现中等两位数百分比的下滑，较2025年同期下降约15%。这一预测反映了市场竞争加剧及专利到期对核心产品带来的持续压力。不过，新一代口服药物Vumerity仍被排除在此次下滑预期之外，显示出公司对创新产品市场表现的信心。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.